Platinum Analogs from a Chemical and Biological Point of View
Date
2022
Type:
Book chapter
item.page.extent
item.page.accessRights
item.contributor.advisor
ORCID:
Journal Title
Journal ISSN
Volume Title
Publisher
item.page.isbn
item.page.issn
item.page.issne
item.page.doiurl
item.page.other
item.page.references
Abstract
Platinum (Pt) analogues are the most widely used chemotherapeutic agents in oncology, used alone or co-administered with other antineoplastic therapy and/or radiation. Pt-based chemotherapies are prescribed to treat a wide spectrum of specific malignancies, including digestive, lung, head and neck, prostate, testicular, ovarian, bladder, cervical, breast, sarcomas and melanomas, as well as several hematological cancers. Patients treated with Pt-based chemotherapies suffer significant adverse effects, limiting their use. Management of these toxic effects is a key factor for successful therapy. Considering that relatively few Pt drugs are clinically and broadly used worldwide, understanding the biochemical and biological basis for resistance to Pt drugs is crucial. Thus, our aim is to summarize current knowledge of the chemical and biological features of Pt-based molecules used in chemotherapy, primarily focusing on its effects on cell function and how some of these changes drive cell resistance to Pt-based molecules.
Description
item.page.coverage.spatial
item.page.sponsorship
Citation
Platinum-Based Chemotherapy: Clinical Uses, Efficacy and Side Effects. Mauricio A. Retamal1,2,3, Ignacio A. Cortés-Fuentes4,5, Juan G. Gormaz6 and Paola R. Campodónico7. 1Universidad del Desarrollo, Programa de Comunicación Celular en Cáncer, Clínica Alemana Facultad de Medicina, Santiago, Chile. Page 1-37. Categories: 2022, Books, Cancer & Cardiology Research, Cancer Etiology, Diagnosis and Treatments, Medicine and Health, Newly Published Books, Nova Medicine and Health, Oncology
Keywords
Cellular resistance, Chemotherapy, Platinum-based treatments, Side effects, Toxicity